Applied Therapeutics Announces Full Data and Scientific Presentations from the Pivotal Phase 2 ACTION-Galactosemia Trial
April 21, 2020 07:00 ET
|
Applied Therapeutics
AT-007 demonstrated rapid and sustained reduction in toxic galactitol levels with no accompanying increase in galactose Positive trend on MRI outcomes, including indirect measures of edema, neuronal...
Applied Therapeutics Announces IND and Investigator-Initiated Studies of AT-001 in Critical COVID-19 Patients
April 02, 2020 07:00 ET
|
Applied Therapeutics
New AT-001 IND opened with FDA for acute lung inflammation and cardiomyopathy in critical COVID-19 patients Hospitals in New York City have commenced investigator-initiated studies; additional...
Applied Therapeutics Reports Fourth Quarter and Year-end 2019 Financial Results
March 13, 2020 07:00 ET
|
Applied Therapeutics
NEW YORK, March 13, 2020 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated...
Applied Therapeutics to Present at the Barclays Global Healthcare Conference
March 10, 2020 07:00 ET
|
Applied Therapeutics
NEW YORK, March 10, 2020 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated...
Applied Therapeutics Appoints Adam Hansard as Chief Commercial Officer
March 03, 2020 07:00 ET
|
Applied Therapeutics
NEW YORK, March 03, 2020 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing novel drug candidates in indications of high unmet...
Applied Therapeutics to Present at the Cowen and Company 40th Annual Health Care Conference
February 26, 2020 16:05 ET
|
Applied Therapeutics
NEW YORK, Feb. 26, 2020 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated...
Applied Therapeutics, Inc. Announces Closing of Public Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares of Common Stock
January 28, 2020 12:24 ET
|
Applied Therapeutics
NEW YORK, Jan. 28, 2020 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (NASDAQ: APLT) (the “Company”), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates...
Applied Therapeutics, Inc. Announces Upsizing and Pricing of Public Offering of 2,741,489 Shares of Common Stock
January 23, 2020 21:28 ET
|
Applied Therapeutics
NEW YORK, Jan. 23, 2020 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (NASDAQ: APLT) (the “Company”), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates...
Applied Therapeutics, Inc. Announces Offering of 1,750,000 Shares of Common Stock
January 21, 2020 16:16 ET
|
Applied Therapeutics
NEW YORK, Jan. 21, 2020 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (NASDAQ: APLT) (the “Company”), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates...
Applied Therapeutics Announces Positive Topline Results of Pivotal Phase 2 ACTION-Galactosemia Study of AT-007 in Galactosemia Patients
January 08, 2020 07:00 ET
|
Applied Therapeutics
AT-007 demonstrated a robust and sustained reduction in galactitol vs placebo; significant plasma galactitol reduction of ~50% (p<0.01) AT-007 was well-tolerated; no drug-related adverse events...